KVUE's Q2 sales and earnings miss estimates, but organic growth improved as Skin Health and Beauty led a broader recovery.

MED's improving coach productivity and client retention point to stabilization, but a shrinking coach base remains a challenge.

DOLE's Q2 earnings miss estimates as higher fruit sourcing, fuel and shipping costs pressured Fresh Fruit, despite strong Americas growth.

Medifast's Trilivy launch and cost cuts could support a Q4 profit turnaround, but shrinking revenue and its coach base keep risks high.

Medifast stock gains 13.6% in a month as improving coach productivity and earnings expectations support momentum despite weaker revenue.

Medifast's low valuation and improving coach productivity offer potential, but a shrinking coach base and weak growth keep the turnaround high risk.

PRMB beats second-quarter earnings and sales estimates, fueled by spring and premium water, and raises its 2026 sales growth outlook.

ADM adjusted earnings nearly double in the second quarter as oilseeds, ethanol and Nutrition gains fuel a raised 2026 outlook.

MED tops Q2 earnings expectations despite lower sales, as rising coach productivity helps offset pressure from a shrinking coach network.

Medifast (MED) delivered earnings and revenue surprises of +58.21% and +1.14%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?